CABA Cabaletta Bio, Inc.
Price Chart
Executive Summary
Cabaletta Bio announced it will present new clinical and translational data from 4 refractory patients treated with rese-cel without preconditioning in the RESET-PV trial at ASGCT 2026. The data showed biologic activity in 2 of 4 patients and a favorable safety profile, but the sample is small and early-stage. No financial impact or guidance changes were disclosed.
Actionable Insight
Monitor the ASGCT presentation on May 14 for full data. Early signs of activity without preconditioning could de-risk the program, but sample is too small to draw conclusions. Expect volatility around the event.
Key Facts
- Data from 4 refractory pemphigus vulgaris patients receiving lowest-dose rese-cel without preconditioning will be presented at ASGCT on May 14, 2026.
- 2 of 4 patients demonstrated compelling clinical activity through 6 months; 3 of 4 remained off all immunomodulators and steroids.
- Complete peripheral B cell elimination observed in 3 of 4 patients; one Grade 1 CRS, no ICANS.
- Higher dose cohort in RESET-PV has been enrolled; durability data expected in H2 2026.
- Initial dose cohort of RESET-SLE (lupus) is fully enrolled; initial data expected in H1 2026.
Financial Impact
No financial figures disclosed; pre-revenue biotech.
Risk Factors
- Small sample size (n=4) limits statistical reliability.
- Early-stage data may not replicate in larger cohorts.
- No financial data or guidance provided; stock may move on sentiment alone.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-202389 |
| Document: 0001193125-26-202389-index-headers.html | 0001193125-26-202389 |
| Document: 0001193125-26-202389-index.html | 0001193125-26-202389 |
| Document: 0001193125-26-202389.txt | 0001193125-26-202389 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $3.00 awaiting T+1 | awaiting T+1 | — | $3.01 (+0.33%) |
|
Jun 3, 2026
11d ago
|
8-K
| $3.58 $3.51 | ▼ −1.96% | ▼ −2.35% | $3.01 (−15.92%) |
|
Jun 1, 2026
13d ago
|
DEFA14A
| $3.67 $3.68 | ▲ +0.27% | ▲ +0.13% | $3.01 (−17.98%) |
|
May 14, 2026
4w ago
|
8-K
| $3.61 $3.31 | ▲ +8.31% | ▲ +7.08% | $3.01 (+16.62%) |
|
May 14, 2026
4w ago
|
Press Release
| $3.61 $3.31 | ▼ −8.31% | ▼ −7.08% | $3.01 (−16.62%) |
|
May 14, 2026
4w ago
|
8-K
| $3.61 $3.31 | ▼ −8.31% | ▼ −7.08% | $3.01 (−16.62%) |
|
May 4, 2026
5w ago
|
8-K
| $3.83 $4.15 | ▼ −8.36% | ▼ −7.56% | $3.01 (+21.41%) |
|
May 4, 2026
5w ago
|
424B5
| $3.83 $4.15 | ▼ −8.36% | ▼ −7.56% | $3.01 (+21.41%) |
|
May 4, 2026
5w ago
|
8-K
| $3.83 $4.15 | ▲ +8.36% | ▲ +7.56% | $3.01 (−21.41%) |
|
Apr 28, 2026
6w ago
|
DEFA14A
| $2.86 $2.78 | ▼ −2.80% | ▼ −2.79% | $3.01 (+5.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access